EP4200285A1 - Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires - Google Patents
Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoiresInfo
- Publication number
- EP4200285A1 EP4200285A1 EP21762623.3A EP21762623A EP4200285A1 EP 4200285 A1 EP4200285 A1 EP 4200285A1 EP 21762623 A EP21762623 A EP 21762623A EP 4200285 A1 EP4200285 A1 EP 4200285A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- skin
- connection
- cosmetic
- isobutyramides
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims description 39
- 238000002360 preparation method Methods 0.000 title claims description 38
- 238000011282 treatment Methods 0.000 title claims description 13
- 238000011321 prophylaxis Methods 0.000 title claims description 11
- 230000002757 inflammatory effect Effects 0.000 title claims description 8
- 150000001875 compounds Chemical class 0.000 title description 3
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical class CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 210000002374 sebum Anatomy 0.000 claims description 31
- 206010000496 acne Diseases 0.000 claims description 30
- 210000004209 hair Anatomy 0.000 claims description 27
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 11
- 208000003251 Pruritus Diseases 0.000 claims description 9
- 208000001840 Dandruff Diseases 0.000 claims description 8
- 230000007803 itching Effects 0.000 claims description 8
- 230000037307 sensitive skin Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- 230000037336 dry skin Effects 0.000 claims description 2
- 229940047889 isobutyramide Drugs 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 67
- 210000001732 sebaceous gland Anatomy 0.000 description 21
- 239000000126 substance Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 206010039792 Seborrhoea Diseases 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 210000004761 scalp Anatomy 0.000 description 9
- 208000008742 seborrheic dermatitis Diseases 0.000 description 9
- 239000000344 soap Substances 0.000 description 9
- 206010015150 Erythema Diseases 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 5
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 239000002453 shampoo Substances 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241001303601 Rosacea Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 201000004700 rosacea Diseases 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical group COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 229940124091 Keratolytic Drugs 0.000 description 2
- SZGGFZROULDDBT-UHFFFAOYSA-N N-[4-(2,4-dihydroxy-3-methylphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound CC(C)C(NC1=NC(C(C=CC(O)=C2C)=C2O)=CS1)=O SZGGFZROULDDBT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 239000008233 hard water Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- 230000001530 keratinolytic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- KAZSKMJFUPEHHW-UHFFFAOYSA-N (2E)-3-[5-(1,1-dimethyl-2-propenyl)-4-hydroxy-2-methoxyphenyl]-1-(4-hdyroxyphenyl)-2-propen-1-one Natural products COC1=CC(O)=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-UHFFFAOYSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 description 1
- OYXZMSRRJOYLLO-KGZHIOMZSA-N 7beta-hydroxycholesterol Chemical compound C([C@@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-KGZHIOMZSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UCTLRSWJYQTBFZ-UHFFFAOYSA-N Dehydrocholesterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CC=C21 UCTLRSWJYQTBFZ-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- KAZSKMJFUPEHHW-DHZHZOJOSA-N Licochalcone A Chemical compound COC1=CC(O)=C(C(C)(C)C=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 KAZSKMJFUPEHHW-DHZHZOJOSA-N 0.000 description 1
- IUCVKTHEUWACFB-UHFFFAOYSA-N Licochalcone A Natural products COC1=CC=C(C(C)(C)C=C)C=C1C=CC(=O)C1=CC=C(O)C=C1 IUCVKTHEUWACFB-UHFFFAOYSA-N 0.000 description 1
- 206010068773 Mechanical urticaria Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JUHBYQVPEUGWBO-UHFFFAOYSA-N N-[4-(2,4-dimethoxyphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound COC1=CC(OC)=CC=C1C1=CSC(NC(=O)C(C)C)=N1 JUHBYQVPEUGWBO-UHFFFAOYSA-N 0.000 description 1
- OQYBNVKSJCRWOU-UHFFFAOYSA-N N-[4-(2-hydroxy-4-methoxyphenyl)-1,3-thiazol-2-yl]-2-methylpropanamide Chemical compound CC(C)C(NC1=NC(C(C=CC(OC)=C2)=C2O)=CS1)=O OQYBNVKSJCRWOU-UHFFFAOYSA-N 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 238000000861 blow drying Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000000409 dermatographia Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000020157 familial dermatographia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004872 foam stabilizing agent Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 229940100608 glycol distearate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- -1 hydroxy-methoxy-phenylthiazole isobutyramide Chemical compound 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001354 painful effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000003779 seborrheic infantile dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
Definitions
- the present invention relates in particular to N-(4-(2,4-dihydroxy- 3-methylphenyl) thiazole-2-yl) isobutyramide and hydroxy-methoxy-phenylthiazole isobutyramide, but also their derivatives, cosmetic and / or dermatological preparations containing them, and their use for the prophylaxis and treatment of sensitive, in particular inflamed skin or inflammatory skin conditions in human skin. Changes associated with the aging process, but also other intrinsic and extrinsic factors (e.g.
- skin irritation is to be understood as meaning any change in the skin that triggers sensory discomfort in humans or animals and/or is characterized by a dry, reddened and/or inflamed complexion.
- sensory discomfort also includes conditions such as itching or pain.
- skin irritation can include phenomenologically different skin conditions: Sensitive skin, sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
- Sensitive skin sensitive skin including a sensitive scalp, vulnerable skin, dry skin, atopic and psoriatic skin, irritated skin, rosacea, inflamed skin, and skin changes in diabetes mellitus, which in each case have a higher degree of severity in a skin reddening, the so-called erythema.
- the problem of "sensitive skin” affects a growing number of adults and children. It is now assumed that up to 50% of the population has sensitive skin (L. Misery et al., Ann. Dermatol. Venereol.2005, 132, 425-4
- Typical disturbing phenomena associated with the terms "stinging” or “sensitive skin” are skin reddening, tingling, tingling, tightening and burning of the skin and itching. They can be caused by stimulating environmental conditions such as B. massage, surfactants, exposure to other chemical substances such. B. lactic acid, weather influences such as heat, cold, drought, but also damp heat, thermal radiation and UV radiation, z. B. the sun, or psychological stress.
- “Sensitive” scalps are also characterized by skin redness, tingling, tingling, burning and itching. Triggers are, for example, soap, shampoo or other hair care products, surfactants, hard water with a high concentration of lime and/or mechanical stress. Erythema and hyperseborrhoea (excessive production of sebum) of the scalp and dandruff are often associated with the phenomena described.
- Atopy a familial hypersensitivity of the skin and mucous membranes to environmental substances, with an increased willingness to react to substances from the natural environment. to develop. Atopy is thought to be genetic. Atopy can manifest itself as atopic dermatitis. The skin barrier is damaged, the skin is often inflamed and itchy.
- the erythematous effect of the ultraviolet part of solar radiation or artificial radiation on the skin is well known. While rays with a wavelength shorter than 290 nm (the so-called UVC range) are absorbed by the ozone layer in the earth's atmosphere, rays in the range between 290 nm and 320 nm, the so-called UVB range, cause erythema, a simple sunburn or even more or less severe burns. Erythematous skin manifestations also occur as side effects of certain skin diseases or irregularities, for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
- certain skin diseases or irregularities for example acne, bacterially induced skin inflammation, cutaneous reactions, dermographism, skin soreness in general, skin moles, erysipelas, shingles, frostbite or burns.
- Rosacea is a special form of reddening of the skin. Anti-inflammatory preparations can therefore also are used to advantage in general, disease-related reddening of the skin and in particular rosacea to subside, to suppress them over a longer period of time and to largely prevent their recurrence.
- Anti-inflammatory agents can therefore also help to reduce the consequences of an insect bite, such as reddening, wheal formation, itching and painful swelling of the skin, suppress them over a longer period of time and prevent them from reoccurring.
- Erythemas also occur more frequently in the diaper area of small children, all the more so in infants (diaper dematitis). Incontinence, a condition that occurs more frequently in older people, is often associated with erythema and reddening of the skin as a result of constant exposure to moisture and irritants (incontinence dermatitis).
- the substances used in cosmetic and/or pharmaceutical products are - toxicologically harmless, - well tolerated by the skin, - stable (in particular in conventional cosmetic and/or pharmaceutical formulations), - preferably faintly odorous or (largely) odorless, - preferably colorless and non-discolouring, and - be inexpensive to produce (ie using standard processes and/or starting from standard precursors).
- an anti-inflammatory active ingredient which preferably fulfills one or more of the aforementioned secondary conditions and particularly preferably all of the aforementioned conditions.
- the present invention relates to the use of topical preparations for removing sebum from the skin, in particular for removing and clearing comedones, for preventing the formation of comedones, for the prophylaxis and treatment of mild forms of acne and for the prophylaxis and control of seborrhea.
- Sebum is the secretion of the sebaceous gland. Sebaceous glands are bulges in the follicular epithelium and are therefore part of the follicle, with which they form a functional unit. They are holocrine glands, which means that most of the gland cell is converted into the secretion sebum. The cells of the sebaceous gland, which are constantly renewed from below, become fatty and disintegrate, and the skin sebum thus formed is emptied through the follicle openings onto the skin's surface.
- the sebum consists of mono -, di- and triglycerides (C 10 -C 18 ), waxes (C 16 -C 26 ), wax esters (C 28 -C 38 ), normal saturated fatty acids (C 10 -C 18 ), branched chain saturated fatty acids (C 11 - C 18 ), polybranched saturated fatty acids (C 13 -C 18 ), monounsaturated fatty acids (C 11 - C 18 ), polyunsaturated fatty acids (C 13 , C 15 -C 17 ), sterols (cholesterol, 7-dehydrocholesterol, 7-hydroxycholesterol), branched and unbranched hydrocarbons (C 30 -C 40 ), squalene and phospholipid
- the lipids of the sebaceous glands form the so-called hydro-lipid film of the skin.
- This surface film is an emulsion, which can be a water-in-oil or an oil-in-water emulsion. It has the function of keeping the skin's surface supple and regulating the water content of the deeper skin layers.
- the sebum When the sebum is well hydrated, the water content is at least 10 to 20% by weight and the sebum is hydrophilic. If the hydrophilic-lipophilic balance of the surface film is no longer given and the water content falls, the sebum changes and becomes hydrophobic. The flow of sebum from the sebaceous gland and follicle is impeded. The sebum accumulates in the follicle openings, which can then lead to comedones and inflammation of the follicles.
- comedones can have various causes. For example: external influences such as incorrect cleaning habits and incorrect care, comedogenic substances in cosmetics, weather influences, alkaline soaps, harsh detergents. Increased sebum secretion and the formation of comedones can also develop as a result of genetic factors and hormonal influences. Here, too, comedones, inflammation, pre-acne and acne with their after-effects can be the result.
- soaps have the disadvantage that the water-insoluble calcium and magnesium salts of the higher fatty acids that form when the soaps are used in hard water form slimy deposits on the skin. If it is difficult to rinse off, these deposits remain on the skin longer, clog the follicle openings and can lead to the formation of comedones. For this reason, syndets (i.e. non-soap tensides) in the form of cleansing creams or cleansing lotions are predominantly used for skin cleansing. Although these syndets do not form lime soaps, treatment with highly surface-active agents has a stronger degreasing and drying effect on the skin than soap.
- Seborrhea is a predisposition to increased function of the sebaceous glands. Both scalp and facial skin appear greasy. The composition of seborrhoeic sebum is different from that of normal sebum. There are 3 stages of seborrhoea development:
- the excessive secretion of the sebaceous glands can be triggered, among other things, by androgenetic disorders and has an aesthetic disadvantage on the overall appearance of the hair. This disorder can also be the cause of hair loss that occurs.
- the precursor to each is the seborrhoeic condition of the scalp. Vegetative disorders and improper care can worsen the complexion and hair condition. Even with seborrhea, the hair itself can be dry due to disturbances in the keratin structure. Dry, damaged hair is often caused by external stress such. B. sun or chemical treatments. Blow-drying that is too hot or not properly caring for damaged hair can lead to damage.
- Greasy hair has very annoying effects.
- the hair becomes stringy again a short time after washing and the hairstyle does not last.
- Greasy hair and dandruff are among the most common hair problems. These anomalies are due to a disturbance in the activity of the sebaceous glands. If the sebaceous glands are overactive, we speak of seborrhea. There are two forms to be distinguished: the oily form (seborrhea oleosa) and the dry form (seborrhea sicca).
- the treatment of seborrhea includes, first of all, regular and thorough washing of the head with special shampoos, which can be carried out as often as seems necessary.
- the wash should be combined with a massage in the connective tissue, because this empties the sebaceous glands more, which delays the subsequent greasing.
- the object of the present invention is to provide a preparation that does not have the disadvantages of the known and previously used agents, which simultaneously has a sebum-dissolving, fat-regulating and caring effect, removes existing comedones without irritation, and degreases and dehydrates the skin effectively prevents the formation of comedones and the development of acne cosmetics, as well as improves existing acne and cares for the skin in the same way.
- Isobutyramides of the general formula where n: means that 1 to 5 identical and/or different substituents R 1 are present can, where the single or multiple substituents R 1 : independently of one another can mean: OH, CH 3 , O-CH 3 , O- (CO) -CH 3 (acetyl), wherein
- R 2 H or a C 1 - C 4 - alkyl chain
- R 3 can be H or CH 3 but excludes the isobutyramide of the structure.
- the isobutyramides according to the invention are excellent active ingredients for the prophylaxis and treatment of sensitive skin, itching and inflammatory phenomena in human skin.
- the active ingredients used according to the invention prevent the formation of seborrheic phenomena, particularly greasy hair but also dandruff, and eliminate existing seborrheic phenomena, particularly greasy hair but also dandruff.
- the present invention ensures very good skin care, combined with efficient removal of excess skin sebum.
- a method for combating impure skin, acne, or seborrheic phenomena, in particular greasy hair and/or dandruff is characterized in that the active ingredients used according to the invention are in a suitable cosmetic or dermatological vehicle with which the increased sebum production is affected Area to be contacted.
- the prior art did not provide the slightest indication of the use according to the invention as an antiseborrheic principle of action.
- a further preferred embodiment of the present invention are therefore formulations to be used against dandruff, for example anti-dandruff shampoos.
- EP 3 176 156 A1 describes similar isobutyramides, but the substances according to the invention are not specifically disclosed in this document.
- EP 3 176 156 A1 is the reduction in skin pigmentation.
- this effect does not occur with the (here) isobutyramides according to the invention and would also be undesirable according to the invention.
- Cosmetic or dermatological preparations according to the invention preferably contain 0.000001 to 10% by weight, particularly preferably 0.0001 to 3% by weight and very particularly preferably 0.001 to 1% by weight of isobutyramides, based on the total weight of the preparations.
- connection 1 isobutyramides for the purposes of the present invention.
- connection 9 connection 10
- the prophylaxis or the cosmetic or dermatological treatment with the active ingredient used according to the invention or with the cosmetic or topical dermatological preparations with an effective content of the active ingredient used according to the invention takes place in the usual way, in such a way that the active ingredient used according to the invention or the cosmetic or topical dermatological preparations with an effective content of active ingredient used according to the invention is applied to the affected skin areas.
- the active ingredient used according to the invention can advantageously be incorporated into customary cosmetic and dermatological preparations, which can be present in various forms. So you can e.g. a solution, an emulsion of the water-in-oil (W/O) or oil-in-water (O/W) type, or a multiple emulsion, for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O), a hydrodispersion or lipodispersion, a Pickering emulsion, a gel, a solid stick or an aerosol.
- W/O water-in-oil
- O/W oil-in-water
- a hydrodispersion or lipodispersion for example of the water-in-oil-in-water type (W/O/W) or oil-in-water-in-oil (O/W/O)
- a hydrodispersion or lipodispersion for example of the water
- Emulsions according to the invention for the purposes of the present invention are advantageous and contain z.
- auxiliaries and additives include, for example, consistency enhancers, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, sunscreens, stabilizers, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytic substances, etc.
- Medicinal topical compositions within the meaning of the present invention usually contain one or more medicaments in an effective concentration.
- cosmetic or topical dermatological compositions according to the present invention can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nourishing cream, day or night cream, etc. It is optionally possible and advantageous to use the compositions according to the invention as a basis to use for pharmaceutical formulations.
- the cosmetic and dermatological preparations according to the invention are applied to the skin and/or the hair in sufficient amounts in the manner customary for cosmetics. upset by the crowd.
- sunscreen preparations which are in the form of a sunscreen are particularly preferred.
- these can additionally contain at least one further UVA filter and/or at least one further UVB filter and/or at least one inorganic pigment, preferably an inorganic micropigment.
- the cosmetic and dermatological preparations can contain cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- cosmetic auxiliaries of the type customarily used in such preparations, eg preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, moisturizing agents and/or moisturizing substances, fats, oils, waxes or other common components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
- An additional content of customary antioxidants is generally preferred. According to the invention, all antioxidants that are suitable or customary for cosmetic and/or dermatological applications can be used as favorable antioxidants.
- the amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05 -
- the cosmetic or dermatological preparation in the sense of the present invention is a solution or emulsion or dispersion, the following can be used as solvents:
- Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
- Fats, waxes and other natural and synthetic fatty substances preferably esters of fatty alcohols with alcohols with a low carbon number, e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids with a low carbon number or with fatty acids;
- Alcohols, diols or polyols with a low carbon number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and analogous products.
- mixtures of the aforementioned solvents are used.
- water can also be an additional component.
- the cosmetic or dermatological preparation according to the present invention is a solution or emulsion or dispersion
- the following solvents can be used: water or aqueous solutions oils such as triglycerides of capric or caprylic acid, but preferably castor oil; - fats, waxes and other natural and synthetic fatty substances, preferably esters of fatty alcohols with alcohols with a low carbon number, e.g.
- mixtures of the aforementioned solvents are used.
- water can also be an additional component.
- suitable propellants for cosmetic and/or dermatological preparations that can be sprayed from aerosol containers are the customary, readily volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or mixed with one another. Compressed air is also advantageous to use.
- Cosmetic preparations within the meaning of the present invention can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents customarily used for this purpose, preferably water, also organic thickeners, for example gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, Hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose or inorganic thickeners, e.g. B. aluminum miniumsilicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
- the thickening agent is contained in the gel, for example, in an amount of between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
- the light protection formulations can advantageously contain further substances which absorb UV radiation in the UVB range, the total amount of the filter substances being, for example, 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, is in particular 1 to 6% by weight, based on the total weight of the preparations, in order to provide cosmetic preparations which protect the skin from the entire range of ultraviolet radiation. They can also serve as sunscreens.
- Leukotrienes which also promote inflammation, can also be formed from arachidonic acid in the skin by migrating neutrophilic granulocytes. Therefore, a reduction in leukotrienes, especially LTB 4 , is recommended for efficient effectiveness.
- Figure 2 demonstrates the reduction of Ca ionophore-stimulated LTB 4
- Granulocytes are the first immune cells to migrate into the skin after an inflammatory stimulus. Although the "oxidative burst" of the granulocytes is very important for the defense against infection, an excessive burst in the tissue can cause major collateral damage. In the case of severe inflammation, it may therefore be advisable to dampen this reaction with anti-inflammatory substances.
- Fig. 3 demonstrates the reduction of the "oxidative burst" of fMLP-stimulated neutrophils
- step 03 Compound 2: N-(4-(2,4-bis(methoxy)phenyl)thiazol-2-yl)isobutyramide Step 01 step 02 step 03 Connections 12 and 13 step 01 step 02 or
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
Nouveaux isobutyramides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020210535.9A DE102020210535A1 (de) | 2020-08-19 | 2020-08-19 | Neue Isobutyramidderivate, kosmetische und/oder dermatologischen Zubereitungen, solche Verbindungen enthaltend, sowie deren Verwendung zur Prophylaxe vor und Behandlung von sensibler, insbesondere entzündeter Haut bzw. entzündlichen Hautzuständen |
PCT/EP2021/071523 WO2022037927A1 (fr) | 2020-08-19 | 2021-08-02 | Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4200285A1 true EP4200285A1 (fr) | 2023-06-28 |
Family
ID=77543471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21762623.3A Pending EP4200285A1 (fr) | 2020-08-19 | 2021-08-02 | Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230312495A1 (fr) |
EP (1) | EP4200285A1 (fr) |
CN (1) | CN116096346A (fr) |
BR (1) | BR112023003093A2 (fr) |
DE (1) | DE102020210535A1 (fr) |
WO (1) | WO2022037927A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116554122B (zh) * | 2023-06-29 | 2023-09-19 | 南京桦冠生物技术有限公司 | α-酮酸酰胺或取代草酸酰胺酯类化合物及其组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102011083259A1 (de) | 2011-09-23 | 2013-03-28 | Beiersdorf Ag | Alkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Alkylamidothiazolen |
DE102013226711A1 (de) | 2013-12-19 | 2015-06-25 | Beiersdorf Ag | Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut |
-
2020
- 2020-08-19 DE DE102020210535.9A patent/DE102020210535A1/de not_active Withdrawn
-
2021
- 2021-08-02 WO PCT/EP2021/071523 patent/WO2022037927A1/fr unknown
- 2021-08-02 BR BR112023003093A patent/BR112023003093A2/pt unknown
- 2021-08-02 EP EP21762623.3A patent/EP4200285A1/fr active Pending
- 2021-08-02 CN CN202180055944.7A patent/CN116096346A/zh active Pending
- 2021-08-02 US US18/041,742 patent/US20230312495A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230312495A1 (en) | 2023-10-05 |
BR112023003093A2 (pt) | 2023-03-28 |
WO2022037927A1 (fr) | 2022-02-24 |
DE102020210535A1 (de) | 2022-03-24 |
CN116096346A (zh) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60313597T2 (de) | Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis | |
EP0847279B1 (fr) | Compositions cosmetiques et/ou pharmaceutiques antiprurigineuses contenant un ou plusieurs anesthesiques locaux legers et un ou plusieurs astringents | |
EP3082752B1 (fr) | Utilisation d'alkylamidothiazoles dans des préparations cosmétiques ou dermatologiques pour assurer la prophylaxie et le traitement des peaux sensibles | |
EP0687467A2 (fr) | Préparations cosmétiques et dermatologiques contenant des éthers de glycerylalkyl comme composant actif | |
DE69916695T2 (de) | Verwendung mindestens eines Hydroxystilben als Mittel zur Verringerung der Adhäsion von Mikroorganismen | |
EP0596284A2 (fr) | Compositions cosmétiques et dermatologiques antimycosiques contenant des esters d'acides gras | |
EP1172084A2 (fr) | Composition cosmétique et dermatologique pour éliminer du sébum | |
DE10025124B4 (de) | Kombinationen von Glycerinmonoalkylethern und Aryl-substituierten Alkoholen | |
EP1179338A1 (fr) | Compositions cosmétiques et dermatologiques comprenant des cyclodextrines pour enlever le sebum | |
EP4200285A1 (fr) | Nouveaux dérivés d'isobutyrylamide, préparations cosmétiques et/ou dermatologiques contenant ces composés et leur utilisation pour la prophylaxie et le traitement de peaux sensibles, en particulier de peaux enflammées ou d'affections cutanés inflammatoires | |
DE19615575A1 (de) | Verwendung von Glucosiden und Ferulasäure als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen | |
DE102005008299A1 (de) | Universalpflegecreme | |
EP2711050A1 (fr) | Composition et préparation cosmétique comprenant une telle composition | |
WO2009115216A1 (fr) | Utilisation d'un constituant ou d'un extrait de baobab en cas de maladies de peau | |
WO2005030157A1 (fr) | Preparations cosmetiques ou dermatologiques a teneur en isoflavones et en licochalcone a | |
EP1377254A2 (fr) | Preparations cosmetiques et dermatologiques contenant des isoflavones | |
EP2560666A1 (fr) | Combinaisons de principes actifs d'extrait d'écorce de magnolia et d'agents tensioactifs (polyglycéryl (3)-méthylglucosedistéarate) | |
EP1834631B1 (fr) | Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et des dérivés de glucose ou des ethers de glycérine | |
EP0620000A3 (fr) | Utilisation cosmétique et/ou pharmaceutique des N-acylalcanolamines | |
EP1383473A2 (fr) | Preparations cosmetiques et dermatologiques renfermant un extrait de houblon ou de houblon-malt et leur utilisation pour la reduction de la secretion de sebum cutane | |
DE19615578A1 (de) | Verwendung von Salix nigra-Extrakt als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen | |
EP2076240B1 (fr) | Préparations cosmétiques ou dermatologiques comprenant de l'ester méthylique de la 2-isopropyl-5- méthyl-cyclohexanecarbonyl-d-alanine et une ou plusieurs substances actives anti-inflammatoires | |
DE19832889A1 (de) | Verfahren zur Isolierung und Reinigung von Fettsäuren und Hydroxyfettsäuren aus Insektenwachsen und deren Verwendung | |
WO2023151898A1 (fr) | Analogues de tofa, préparations de réduction de sébum contenant ledit type d'analogues et utilisation cosmétique et/ou thérapeutique dudit type d'analogues en tant que principe efficace pour réduire ou prévenir le sébum | |
WO2018099675A1 (fr) | Utilisation de 2'-méthoxyflavones dans des préparations cosmétiques ou dermatologiques pour la prophylaxie et le traitement des peaux sensibles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230420 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEIERSDORF AG |